Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12329374 | 0.77 | HRH1 (0.56) | HTR2ATAAR1HRH1LMNATDP1 | |
| SCHEMBL31439740 | 0.75 | LMNA (0.65) | TAAR1LMNARAB9A | |
| SCHEMBL13715906 | 0.75 | TAAR1 (0.58) | TAAR1LMNA | |
| SCHEMBL3290730 | 0.73 | HRH1 (0.68) | HTR2ATAAR1HRH1LMNATDP1 | |
| SCHEMBL9838705 | 0.73 | HTR2A (0.58) | HTR2ATAAR1HRH1TDP1DPP4 | |
| SCHEMBL2732016 | 0.71 | HRH1 (0.65) | HTR2ATAAR1HRH1LMNATDP1 | |
| SCHEMBL844862 | 0.71 | HRH1 (0.65) | HTR2ATAAR1HRH1LMNATDP1 | |
| SCHEMBL38652540 | 0.71 | HTR2A (0.89) | HTR2ATAAR1HRH1DPP4F2 | |
| SCHEMBL7800345 | 0.69 | CA12 (0.47) | HTR2ATAAR1HRH1LMNATDP1 | |
| SCHEMBL29280865 | 0.69 | HRH1 (0.54) | HTR2ATAAR1HRH1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130380-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
| US-5594079-A | COORDINATION CATALYST CONTAINING BORON, STEREOREGULAR POLYPROPYLENE | TOSOH CORPORATION (JP) | 1997-01-14 | — | — | US | disclosed |
| EP-0582278-A2 | Method for producing a polyolefin | TOSOH CORPORATION (JP) | 1994-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130380-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV5, TRPA1 | HTR2A 3066/4885TAAR1 1018/4885HRH1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.